Sign inCreate account

Report workspace

Add to folder
NCT04035434TERMINATEDanonymous

A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)

Sponsor

Source record

CRISPR Therapeutics AG

Phase

Source record

Phase 1/2

Modality

AI-normalized

gene therapy

Target

AI-normalized

CD19-directed chimeric antigen receptor (CAR) T cells engineered using CRISPR-Cas9 technology.

Indication / condition

AI-normalized

B-cell Malignancy

Intervention

Source record

CTX110

Source & freshness

Source record

NCT ID

NCT04035434

Original source

ClinicalTrials.gov

Source last updated

Oct 24, 2025

Ingested at

Jun 16, 2026

Internal sync

Jun 16, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT04035434

Title

A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)

Sponsor

CRISPR Therapeutics AG

Status

TERMINATED

Phase

Phase 1/2

Condition raw

B-cell Malignancy, Non-Hodgkin Lymphoma, B-cell Lymphoma, Adult B Cell ALL

Condition normalized

B-cell Malignancy, Non-Hodgkin Lymphoma, B-cell Lymphoma, Adult B Cell ALL

Modality raw

gene therapy

Modality normalized

gene therapy

Target raw

CD19-directed chimeric antigen receptor (CAR) T cells engineered using CRISPR-Cas9 technology.

Target normalized

CD19-directed chimeric antigen receptor (CAR) T cells engineered using CRISPR-Cas9 technology.

Interventions

CTX110

Public preview

Source record

CRISPR Therapeutics AG's CTX110 is positioned within the competitive landscape of CAR T-cell therapies targeting B-cell malignancies, specifically non-Hodgkin lymphoma (NHL) and B-cell acute lymphoblastic leukemia (ALL). The market for CAR T therapies is growing, driven by increasing incidences of hematological malignancies and advancements in gene editing technologies. However, the termination of the CARBON study indicates potential challenges in achieving clinical efficacy or safety benchmarks, which may impact investor confidence and future funding. The ongoing follow-up in the CRSP-ONC-LTF study suggests a strategic pivot to gather additional data, which may influence future market positioning and partnership opportunities.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 16, 2026

NCT ID

NCT04035434

Status

TERMINATED

Phase

Phase 1/2

Sponsor

CRISPR Therapeutics AG

Executive brief

Investment-Ready Snapshot

CRISPR Therapeutics AG's CTX110 is positioned within the competitive landscape of CAR T-cell therapies targeting B-cell malignancies, specifically non-Hodgkin lymphoma (NHL) and B-cell acute lymphoblastic leukemia (ALL). The market for CAR T therapies is growing, driven by increasing incidences of hematological malignancies and advancements in gene editing technologies. However, the termination of the CARBON study indicates potential challenges in achieving clinical efficacy or safety benchmarks, which may impact investor confidence and future funding. The ongoing follow-up in the CRSP-ONC-LTF study suggests a strategic pivot to gather additional data, which may influence future market positioning and partnership opportunities.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedOct 24, 2025
Internal syncJun 16, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04035434

Indication

B-cell Malignancy

Modality

gene therapy

Target

CD19-directed chimeric antigen receptor (CAR) T cells engineered using CRISPR-Cas9 technology.

Intervention

CTX110

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.